MANE

VERADERMICS INC

• TipRanks·7h ago

  Buy/High Risk Stance Reaffirmed on Strong Phase 3 Hair-Loss Data; $160 Price Target Unchanged

• Benzinga·23h ago

  Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough

• Dow Jones·1d ago

  Veradermics Shares Rise After Positive Data for VDPHL01 Trial

• Benzinga·1d ago

  Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday

• TipRanks·1d ago

  Veradermics Reports Strong Phase 3 Hair Loss Results

• Benzinga·1d ago

  Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday

• Seeking Alpha·1d ago

  Veradermics scores another late-stage trial win for hair loss therapy

• Dow Jones·1d ago

  Veradermics Is Maintained at Buy by Needham

• Dow Jones·1d ago

  Veradermics Price Target Raised to $172.00/Share From $164.00 by Needham

• Benzinga·1d ago

  Cantor Fitzgerald Reiterates Overweight on Veradermicsto Overweight

• Benzinga·1d ago

  Needham Maintains Buy on Veradermics, Raises Price Target to $172

• Benzinga·1d ago

  Veradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile

• TipRanks·1d ago

  Veradermics announces trial of VDPHL01 met primary, secondary endpoints

• NASDAQ·1d ago

  Veradermics To Review Phase 3 Study 304 Results For VDPHL01 In Male Pattern Hair Loss; Stock Up

• TipRanks·5d ago

  Citi Sticks to Their Buy Rating for Veradermics, Incorporated (MANE)